Prognostic value of systemic immune-inflammation index in patients with locally advanced renal cell carcinoma
Open Access
- 30 September 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Urological Science
- Vol. 35 (3) , 121-126
Abstract
Purpose: To assess the prognostic value of systemic immune-inflammation index (SII) for disease progression in locally advanced renal cell carcinoma (RCC). Materials and methods: A total of 97 patients with locally advanced RCC who underwent curative surgery between January 1, 2010 and December 31, 2018 were included in this retrospective study. The study was approved by the Institutional Review Board of Linkou Chang Gung Memorial Hospital with an IRB number of 202000092B0. Outcomes analyzed were the disease-free survival (DFS) of patients with locally advanced RCC and the prognostic value of SII. Results: Among 97 locally advanced RCC patients, disease progression was noted in 48.5% of the patients. The median DFS was 55.6 months (95% confidence interval: 45.1–66.2 months). An elevated SII greater or equal to 514 was associated with a poorer DFS. After multivariate analyses of possible predictive factors, SII remained statistically associated with a poorer DFS. Conclusion: An elevated SII was associated with a poorer DFS in patients with locally advanced RCC. SII could be used as a prognostic factor to guide the use of adjuvant therapy after curative surgery for patients with locally advanced RCC.Keywords
This publication has 20 references indexed in Scilit:
- Circulating tumor cell-blood cell crosstalk: Biology and clinical relevanceCell Reports, 2022
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell CarcinomaNew England Journal of Medicine, 2021
- Predictive factors of recurrence after surgery in patients with non-metastatic renal cell carcinoma with venous tumor thrombus (UroCCR-56 Study)World Journal of Urology, 2021
- Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell CarcinomaEuropean Urology, 2021
- Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinomaInternational Urology and Nephrology, 2020
- Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trialAnnals of Oncology, 2018
- Prognostic factors and prognostic models for renal cell carcinoma: a literature reviewWorld Journal of Urology, 2018
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyNew England Journal of Medicine, 2016
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialThe Lancet, 2016
- Hallmarks of Cancer: The Next GenerationCell, 2011